In my position as program director for the Endocrinology and Physiology Program, I coordinate scientific portfolios for bone research, neuroendocrinology, and clinical endocrinology. The bone program encompasses basic and clinical research on the hormonal regulation of bone and mineral metabolism in health and disease, endocrine aspects of disorders affecting bone, all facets of parathyroid disorders, the effects of systemic or local-acting hormones and their receptors on bone metabolism, bone-active cytokines, studies of calcium-related processes, basic and clinical studies of vitamin D, bone morphogenesis, and studies addressing the impact of metabolic derangements in Type 1 and Type 2 diabetes mellitus on the skeleton.
My other research interests lie within studies surrounding neuroendocrinology that examine a range of topics, including the physiological response to stress through the hypothalamic-pituitary-adrenal axis, neuropeptides and their signaling pathways, gene regulation in the hypothalamus and pituitary gland, diseases of the pituitary, pituitary hormone receptors and actions on target tissues, and neuroendocrine-immune interactions.
My work for the Division of Diabetes, Endocrinology, and Metabolic Diseases also includes evaluation of human subject protection for all clinical research. I am also a member of the Trans NIH research group that addresses various topics on bone health. I represent the NIDDK on the ACCORDION (the longitudinal follow-up study of patients previously involved in the Action to Control Cardiovascular Risk in Diabetes Trial) Study, which is led by the National Heart, Lung, and Blood Institute. Finally, I am the program officer of The Vitamin D and Type 2 Diabetes Study (D2d study), a randomized multicenter placebo-controlled study assessing the safety and efficacy of vitamin D to prevent or delay the development of type 2 diabetes in subjects at risk.